Biopharma & Life Sciences
Pacific BioSciences of California Executive Compensation (FY25)
PACB · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 4, 2026
152 figures on this page: 146 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christian Henry: $9,181,620 → $4,309,846 (53.1% lower)
Say-on-pay support: 60.4% → 83.1% (22.7 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Pacific BioSciences of California's chief executive and what were they paid?
Christian Henry was paid $4,309,846 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $9,181,620 reported for fiscal 2024, Henry's total was 53.1% lower.
What was Pacific BioSciences of California's say-on-pay result?
The say-on-pay proposal drew 83.1% of votes cast including abstentions in favor at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in Pacific BioSciences of California's peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., AbCellera Biologics Inc., Adaptive Biotechnologies Corporation, Azenta, Inc. and Castle Biosciences, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christian Henry President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mark Van Oene Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christian Henry President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Mark Van Oene Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Christian Henry President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Jim Gibson Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Mark Van Oene Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Christian O. Henry | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christian O. Henry | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jim R. Gibson | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jim R. Gibson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Jim R. Gibson | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Mark Van Oene | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mark Van Oene | Options/SARs | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jim Gibson | Option | ◇ | — | ◇ | 3/31/2035 |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/31/2035 | |
| Mark Oene | PSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/2/2032 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/19/2035 | |
| Christian Henry | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 3/19/2035 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/2/2032 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Christopher M. Smith | ◇ | ◇ | ◇ | — | — | — | ◇ |
John F. Milligan, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Marshall Mohr | ◇ | — | ◇ | — | — | — | ◇ |
William Ericson | ◇ | — | ◇ | — | — | — | ◇ |
Kathy Ordoñez | ◇ | — | ◇ | — | — | — | ◇ |
Randy Livingston | ◇ | — | ◇ | — | — | — | ◇ |
Lucy Shapiro, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Hannah A. Valantine, M.D | ◇ | — | ◇ | — | — | — | ◇ |
David Meline | ◇ | — | — | — | — | — | ◇ |
Christian O. Henry and Chris Gibson, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10x Genomics, Inc. TXG
- AbCellera Biologics Inc. ABCL
- Adaptive Biotechnologies Corporation ADPT
- Azenta, Inc. AZTA
- Castle Biosciences, Inc. CSTL
- Cytek Biosciences, Inc. CTKB
- Fulgent Genetics, Inc. FLGT
- Ginkgo Bioworks, Inc. DNA
- Guardant Health, Inc. GH
- Myriad Genetics, Inc. MYGN
- NeoGenomics, Inc. NEO
- Quanterix Corporation QTRX
- Repligen Corporation RGEN
- Twist Bioscience Corporation TWST
- Veracyte, Inc. VCYT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 3, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 18, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 24, 2023 | = | ◇ | ◇ | ◇ |
| 2019 | August 4, 2020 | = | ◇ | ◇ | ◇ |
| 2016 | May 24, 2017 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Pacific BioSciences of California disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pacific BioSciences of California sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
152 figures on this page: 146 cited to the filing that reported them, 6 calculated from figures it prints.
146 cited to the filing
6 calculated from the filing
Documents cited
- 0001299130-26-000092Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001299130-26-000064Director Compensation · Director Compensation for Fiscal Year 2025 · Outstanding Equity Awards at Fiscal Year-End 2025 · Summary Compensation Table for Fiscal Years 2025, 2024 and 2023 · and 2 more sections
- 0001299130-25-000140Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001299130-25-000090Summary Compensation Table for Fiscal Years 2024, 2023 and 2022
- 0001299130-24-000146Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001299130-24-000097Summary Compensation Table for Fiscal Years 2023, 2022 and 2021
- 0001299130-23-000070Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001299130-20-000116Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001299130-17-000040Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pacific BioSciences of California executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/PACB (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pacific BioSciences of California and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Pacific BioSciences of California discloses
The companies named in PACB's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}